Century Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Century Therapeutics, Inc. (IPSC) reported Increase Decrease In Operating Lease Liability of -$1.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-12
- Century Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$989.00K.
- Century Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$786.00K.
- Century Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$1.40M.
- Century Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$1.23M.
- Century Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$4.98M.
- Century Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$3.37M, a 124.35% decline from fiscal 2023.
- Century Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was $13.82M, a 162.82% increase from fiscal 2022.
- Century Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was $5.26M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$989.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.77M 10-Q · filed 2026-08-12 | -$3.17M derived: sum of 3 quarters · filed 2026-08-12 | -$4.41M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$786.00K 10-Q · filed 2026-05-13 | -$2.19M derived: sum of 2 quarters · filed 2026-05-13 | -$3.42M derived: sum of 3 quarters · filed 2026-05-13 | -$4.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$2.63M derived: sum of 2 quarters · filed 2026-03-12 | -$3.82M derived: sum of 3 quarters · filed 2026-08-12 | -$4.98M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.42M derived: sum of 2 quarters · filed 2026-08-12 | -$3.58M 10-Q · filed 2025-11-13 | -$4.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.35M 10-Q · filed 2026-08-12 | -$3.11M derived: sum of 3 quarters · filed 2026-08-12 | -$5.85M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$1.15M 10-Q · filed 2026-05-13 | -$1.92M derived: sum of 2 quarters · filed 2026-05-13 | -$4.66M derived: sum of 3 quarters · filed 2026-05-13 | -$2.33M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$3.50M derived: sum of 2 quarters · filed 2026-03-12 | -$1.18M derived: sum of 3 quarters · filed 2026-03-12 | -$3.37M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$413.00K derived: sum of 2 quarters · filed 2025-11-13 | -$2.60M 10-Q · filed 2025-11-13 | -$227.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $140.00K 10-Q · filed 2025-08-14 | $2.51M derived: sum of 3 quarters · filed 2025-08-14 | $7.24M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$2.19M 10-Q · filed 2025-05-15 | $186.00K derived: sum of 2 quarters · filed 2025-05-15 | $4.91M derived: sum of 3 quarters · filed 2025-05-15 | $7.79M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $7.10M derived: sum of 2 quarters · filed 2025-03-19 | $9.98M derived: sum of 3 quarters · filed 2025-03-19 | $13.82M 10-K · filed 2025-03-19 |
| 2023-09-30 | $4.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $7.61M derived: sum of 2 quarters · filed 2024-11-05 | $11.45M 10-Q · filed 2024-11-05 | $13.51M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $2.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $6.72M 10-Q · filed 2024-08-08 | $8.79M derived: sum of 3 quarters · filed 2024-08-08 | $9.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.84M 10-Q · filed 2024-05-09 | $5.91M derived: sum of 2 quarters · filed 2024-05-09 | $6.62M derived: sum of 3 quarters · filed 2024-05-09 | $9.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.78M derived: sum of 2 quarters · filed 2024-03-14 | $5.41M derived: sum of 3 quarters · filed 2024-03-14 | $5.26M 10-K · filed 2024-03-14 |
| 2022-09-30 | $715.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.35M derived: sum of 2 quarters · filed 2023-11-09 | $3.19M 10-Q · filed 2023-11-09 | $2.98M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $2.48M 10-Q · filed 2023-08-09 | $2.26M derived: sum of 3 quarters · filed 2023-08-09 | $2.31M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$152.00K 10-Q · filed 2023-05-11 | -$369.00K derived: sum of 2 quarters · filed 2023-05-11 | -$325.00K derived: sum of 3 quarters · filed 2023-05-11 | -$320.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$217.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$173.00K derived: sum of 2 quarters · filed 2023-03-16 | -$168.00K derived: sum of 3 quarters · filed 2023-03-16 | -$41.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $49.00K derived: sum of 2 quarters · filed 2022-11-10 | $176.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $132.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $127.00K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $2.17M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |